The European Cannabis Import Race: Germany Consumed 142 Tonnes in 9 Months — Who’s Supplying It?

What does this mean for the global cannabis industry?

In the first nine months of 2025, Germany imported 142 tonnes of medical cannabis — surpassing the country’s entire annual import quota of 122 tonnes and forcing the Federal Institute for Drugs and Medical Devices (BfArM) to raise the ceiling by another 70 tonnes in October. By December, the year-end total reached 201,094 kg, nearly tripling the 72,706 kg recorded in 2024. Those numbers did not appear in a vacuum. They are the direct consequence of Germany’s Cannabis Act (CanG), which removed cannabis from the Narcotics Act in April 2024 and triggered a 3,300% increase in prescriptions within 18 months.

But the demand side of the equation is only half the story. The more consequential question for international cultivators, supply chain managers, and European operators is this: who supplied those 201 tonnes, who is gaining market share, and who risks being left behind?

The answer involves a transatlantic supply chain stretching from British Columbia to the Alentejo, a handful of EU-GMP certified facilities acting as bottlenecks, and a competitive landscape that is shifting faster than most producers anticipated. Understanding the dynamics of European cannabis imports 2025 is essential for any company considering commercializing cannabis products internationally — because the rules of the game are being rewritten in real time.

Germany’s 142-Tonne Appetite: A Quarter-by-Quarter Breakdown

Germany’s medical cannabis imports in 2025 followed a steep growth curve through the first three quarters before plateauing in Q4. The BfArM data reveals both the scale of acceleration and the first signs of demand normalization.

Quarterly Import Volumes: 2024 vs. 2025

Several dynamics drove this trajectory. The CanG legislation, effective April 1, 2024, removed cannabis from Schedule I of Germany’s Narcotics Act and introduced the Medical Cannabis Act (MedCanG). This eliminated the requirement for special narcotic prescriptions and enabled standard pharmaceutical prescribing, which dramatically reduced the administrative burden on physicians. Telemedicine platforms then scaled access at an unprecedented rate, with cannabis prescriptions increasing 3,300% between March 2024 and December 2025 according to Bloomwell Group’s Cannabis Barometer.

The Quota Crisis

By September 2025, Germany had exhausted its 122-tonne annual import quota. BfArM paused new import approvals — not a formal import stop, the agency emphasized, but a delay while it reassessed the ceiling. On October 20, BfArM raised the national import limit to 192.5 tonnes and resumed approvals. That revised ceiling was itself exceeded by year-end, with actual imports reaching 201 tonnes.

The Q4 slowdown to 56,625 kg (down from Q3’s 59,076 kg) represents the first quarterly decline in the post-CanG era. Analysts attribute this to a combination of the October quota freeze, incoming regulatory amendments targeting telemedicine prescribing, and seasonal effects. Health Minister Nina Warken’s draft amendments, approved by the German Cabinet in October 2025, would ban new remote cannabis prescriptions and restrict mail-order cannabis sales — measures that could fundamentally reshape demand trajectories in 2026.

The Supplier Rankings: Who Shipped What in 2025

The European cannabis supply chain remains highly concentrated. Two countries — Canada and Portugal — accounted for approximately 74% of Germany’s total 2025 imports. But the competitive landscape beneath that duopoly is shifting.

Germany’s Cannabis Suppliers: Full-Year 2025 Import Data

Canada: Still the Engine, But Losing Market Share

Canada remains the single largest supplier to Germany, shipping 93,006 kg in 2025 — up from 33,155 kg in 2024. In absolute terms, Canada’s exports to Germany nearly tripled. Yet its market share declined from approximately 58% in early 2024 to 46% by year-end 2025. Canada’s total global cannabis exports reached 240 tonnes in 2025, more than double the 107 tonnes exported in 2024, with Germany as the primary destination.

The declining share reflects not Canadian weakness but the accelerating growth of competitors, particularly Portugal. It also reflects a structural feature of the supply chain: a significant portion of Canadian-origin cannabis is shipped to Portugal for EU-GMP processing before re-export to Germany. This "transatlantic triangle" — Canada to Portugal to Germany — means that Portugal’s import figures include substantial Canadian-grown product, and Canada’s true influence on the German market is larger than its direct shipment numbers suggest.

Portugal: The Processing Hub

Portugal shipped 55,164 kg to Germany in 2025, up from 17,230 kg in 2024 — a 220% increase that cemented the country as Europe’s dominant cannabis processing gateway. With 125 authorized medicinal cannabis companies and 25 EU-GMP certified facilities, Portugal serves as the critical intermediary between global cultivation and European patient markets. Through GrowerIQ’s partnership with LEF Lab/InfoSaude in Portugal, the company supports operators navigating this complex export corridor.

The Emerging Challengers

The most dramatic percentage gains came from smaller supplier countries. Malta’s shipments exploded from 161 kg to 4,858 kg — a nearly 3,000% increase — positioning the island nation as a serious emerging player. Australia more than tripled its exports to Germany, reaching 4,190 kg. Denmark rebounded with 9,319 kg after a production lull in 2023, reclaiming its position as the third-largest supplier. The Czech Republic, buoyed by regulatory reforms enabling commercial cultivation, also recorded significant year-over-year gains.

These smaller players collectively grew from approximately 15% to over 20% of total imports, signaling a gradual diversification of Germany’s supply base.

EU-GMP: The Ticket to Entry

No cannabis product enters the German pharmaceutical market — or any other regulated European market — without EU-GMP (Good Manufacturing Practice) certification. This certification is the single most important barrier to entry for international cannabis exporters, and understanding its requirements is essential for anyone pursuing the European cannabis supply chain.

What EU-GMP Requires

EU-GMP certification demonstrates that a manufacturing facility consistently produces products according to quality standards appropriate for pharmaceutical use. For cannabis specifically, this means:

Facility Requirements:

• Cleanroom environments with defined air classification (typically ISO Class 7 or 8 for primary production areas)
• HVAC systems with HEPA filtration and environmental monitoring
• Controlled access points with gowning procedures
• Segregated areas for different production stages to prevent cross-contamination
• Pharmaceutical-grade water systems
• Validated pest management and environmental controls

Quality Systems:

• Comprehensive Quality Management System (QMS) with documented SOPs for every process
• Validated manufacturing processes with in-process controls
• Thorough in-process and finished-product testing, including identity, potency, microbial contamination, heavy metals, pesticide residues, and mycotoxins
• Detailed batch records and full production documentation
• Stability testing programs and validated shelf-life assignments
• Change control and deviation management systems
• Annual product quality reviews

Personnel:

• Qualified Person (QP) responsible for batch release — a pharmacist or equivalent with specific regulatory training
• Ongoing GMP training programs for all staff
• Defined organizational structure with clear quality responsibilities

Timeline and Cost

Obtaining EU-GMP certification is a rigorous and capital-intensive process:

Application timelines vary dramatically by jurisdiction. Portugal’s INFARMED has historically processed applications in 6-12 months; Germany’s regional authorities may take 12-24 months. The UK’s MHRA charges GBP 6,019 for new Manufacturing Authorisation applications but the inspection process itself adds months.

The 2026 CSQ Addendum

In May 2026, the Cannabis Specific Quality (CSQ) scheme published its new EU GMP Addendum for industry stakeholders, with audits to the finalized Addendum commencing in Q4 2026. This addendum introduces cannabis-specific interpretations of EU-GMP requirements, potentially creating a more standardized audit framework across European authorities. Operators who are not tracking these developments risk finding their existing certifications insufficient under the revised standards.

Beyond Germany: The Broader European Import Map

Germany dominates the headlines, but European cannabis imports 2025 extend well beyond a single market. At least five other countries are building significant import-dependent medical cannabis markets, and their collective demand is accelerating.

United Kingdom: The Fastest-Growing Patient Market

The UK’s private medical cannabis market has experienced explosive growth. Prescriptions surged 262% between 2022 and 2024, from 283,000 to 659,000, while flower volumes grew from 2,700 kg to nearly 10,000 kg over the same period. By the end of 2025, an estimated 80,000 patients were receiving treatment through the UK system, with annual imports projected to exceed 20 tonnes.

The UK market is valued at over EUR 300 million in 2025, and at current growth rates, annual medical cannabis sales in the UK are projected to outstrip those of Israel and Canada by 2026. The primary suppliers are Canada, Spain, and Portugal. Notably, 16 companies now hold licenses to cultivate high-THC cannabis domestically, though imports remain the dominant supply source.

Poland: Europe’s Quiet Cannabis Giant

Poland is Europe’s fourth-largest medical cannabis market, projected at EUR 72 million in 2025 with over 105,000 registered patients. All medical cannabis sold in Poland is imported, with Portugal and Canada dominating the supply chain. Poland imported approximately 7.8 tonnes in 2024, driven by the rapid expansion of telemedicine platforms — though government restrictions on remote prescribing are beginning to curb this growth.

Czech Republic: From Importer to Exporter

The Czech Republic occupies a unique position as both importer and emerging exporter. Regulatory reforms have enabled commercial cultivation, and over 1,300 kg of Czech-grown medical cannabis was shipped to Germany in 2024. Domestically, the Czech market continues to import for patient supply while simultaneously building export-oriented cultivation capacity.

Understanding the regulatory frameworks in these markets requires navigating country-specific rules — from cannabis club founding requirements in Germany to the documentation and reporting requirements for cannabis in Germany that govern domestic production and distribution.

Italy and the Netherlands: Controlled Markets

Italy remains tightly regulated, with state-controlled cultivation and procurement through the military pharmaceutical facility in Florence and limited imports via Bedrocan from the Netherlands. Despite being one of Europe’s earliest medical cannabis adopters, Italy’s market remains small relative to its population due to restrictive access policies.

The Netherlands exports approximately 4 tonnes annually, primarily through Bedrocan, with the government managing all external supply contracts. Exports are directed mainly to Germany and Italy, while the domestic Dutch market remains modest in volume terms.

European Import Volume Summary

Supply Chain Challenges and Bottlenecks

The rapid scaling of European cannabis imports 2025 has exposed structural weaknesses across the supply chain. Operators who understand these bottlenecks can position themselves to capture market share; those who ignore them risk costly delays and lost contracts.

The Portugal Processing Bottleneck

Portugal’s central role as Europe’s processing hub has created a single point of fragility. Export permit processing times have stretched from approximately 30 days to over 70 days, creating significant delays where GACP-certified product from Canada sits in Portuguese warehouses for months before moving to Germany or the UK. Pharmacies expect at least a year of guaranteed shelf life under GMP conditions, but wholesalers are increasingly reluctant to accept aged product — creating a buildup of inventory that degrades in value with each passing month.

Companies are responding by diversifying their processing routes. The Czech Republic, Malta, and North Macedonia are attracting investment as alternative processing hubs, and the trend toward vertical integration — grow, process, and export from a single jurisdiction — is accelerating.

Price Compression

Three years of sustained price compression on dried flower and oil products has squeezed margins across the supply chain. As new EU-GMP certified capacity came online faster than prescription volumes could absorb it, wholesale prices for standard medical cannabis flower in Germany declined significantly. EU-GMP certified products still command a premium, but the gap is narrowing. Bulk cannabis prices in Germany have collapsed under supply pressure, forcing producers to compete on quality differentiation, strain exclusivity, and operational efficiency rather than simply holding certification.

Regulatory Uncertainty

Germany’s proposed amendments to the CanG framework — including restrictions on telemedicine prescribing and mail-order sales — represent the most significant regulatory risk facing the European cannabis supply chain. If enacted as drafted, these measures could reduce new patient enrollment substantially in 2026, directly impacting import volumes. The Q4 2025 slowdown in imports may be an early indicator of this chilling effect.

Logistics and Cold Chain

Cannabis shipments between continents require specialized pharmaceutical logistics: GDP (Good Distribution Practice) compliant transport, temperature-controlled shipping, customs documentation, and import/export permits from multiple regulatory authorities. Each handoff point introduces delay risk. The average time from harvest in Canada to pharmacy shelf in Germany can exceed 6-8 months, a timeline that is incompatible with patient expectations for fresh, potent product.

The Competitive Outlook: Who Wins the Import Race?

The European cannabis import market is entering a phase of maturation. The explosive growth of 2024-2025, driven by Germany’s legislative reform, is giving way to a more complex competitive landscape where success depends on operational excellence, regulatory agility, and strategic positioning.

Canada: Scale Advantage, Distance Disadvantage

Canada’s licensed producers hold an unmatched scale advantage — the country’s total export capacity far exceeds any competitor. But distance and transit times are structural liabilities. Canadian product shipped through Portuguese intermediaries accumulates processing delays, shelf-life erosion, and additional cost layers. The winners among Canadian exporters will be those who establish direct EU-GMP certified operations in Europe or secure vertically integrated partnerships that eliminate intermediary steps.

Portugal: Gateway Under Pressure

Portugal’s position as Europe’s processing gateway is not guaranteed. Rising permit delays, potential regulatory reforms by INFARMED, and the emergence of alternative processing jurisdictions are all eroding the country’s competitive moat. Companies with established, efficient Portuguese operations will continue to thrive, but new entrants may find faster routes to market through Malta, the Czech Republic, or direct-to-Germany certification.

Denmark and the Nordic Corridor

Denmark’s recovery to 9,319 kg in exports to Germany signals a reestablishment of the Nordic corridor. With strong pharmaceutical infrastructure and proximity to German markets, Denmark offers transit time advantages that transatlantic suppliers cannot match. Expect Denmark to capture a growing share of the premium segment.

Southern European Cultivators

Spain, North Macedonia, and Greece offer lower cultivation costs and favorable growing climates, but their EU-GMP certification infrastructure remains underdeveloped compared to Portugal and Denmark. These countries represent medium-term opportunities for investors willing to build pharmaceutical-grade facilities from the ground up.

The Vertical Integration Trend

The overriding strategic trend is toward vertical integration. The most competitive operators in 2026 and beyond will control the entire chain — cultivation, EU-GMP processing, and direct export to destination markets — eliminating the intermediary dependencies that currently add months and significant cost to the supply chain. This is the shift that will ultimately determine who wins the European cannabis import race.

How GrowerIQ Supports International Cannabis Exporters

Navigating the European cannabis supply chain demands more than good genetics and a greenhouse. It requires real-time traceability from seed to sale, batch documentation that satisfies EU-GMP auditors across multiple jurisdictions, and quality management systems that scale with rapidly growing export volumes.

GrowerIQ’s seed-to-sale platform is purpose-built for this challenge. The system provides:

• EU-GMP Compliant Batch Records: Digital master batch records that capture every data point auditors require — from cultivation parameters through processing, testing, and packaging — in a single, auditable system.
• Multi-Jurisdiction Traceability: Track product from Canadian cultivation through Portuguese processing to German pharmacy shelves, with full chain-of-custody documentation at every handoff.
• CFR Part 11 Digital Signatures: Tamper-evident electronic signatures that meet both FDA and EU regulatory requirements for pharmaceutical manufacturing records.
• Automated Reporting: Generate BfArM-compliant import documentation, INFARMED export permits, and MHRA submission packages from the same underlying data.
• Quality Analytics: Real-time COGS tracking, yield analytics, and quality trend monitoring that help exporters optimize production while maintaining compliance.

For operators targeting the European market, compliance is not a feature — it is the product. Every kilogram that fails to meet EU-GMP documentation standards is a kilogram that does not reach a patient or generate revenue.

Whether you are a Canadian LP scaling exports, a Portuguese processor managing throughput, or a new market entrant building EU-GMP capacity from scratch, understanding the competitive dynamics of the European cannabis import market is the first step toward capturing your share of a market that exceeded EUR 1 billion in 2025. For more background on the global cannabis landscape, explore these key facts about the cannabis industry and how rapidly the international trade landscape has evolved.

This analysis is current as of May 2026 and draws on the EU Drugs Agency (EUDA) European Drug Report 2025 and reporting from the International Cannabis Business Conference, StratCann, and Business of Cannabis. Trade figures reflect the best available data as of the publication date.

Sources

• Germany Imported Over 201 Tonnes Of Medical Cannabis In 2025 — International Cannabis Business Conference
• Germany Imported Over 43 Tonnes Of Cannabis In Q2 2025 — International Cannabis Business Conference
• Germany Medical Cannabis Imports Top 200 Tonnes in 2025 — Business of Cannabis
• Germany Increases Medical Cannabis Import Limit by 70 Tonnes — StratCann
• German Cannabis Prescriptions Increased 3,300% From 2024 To 2025 — International Cannabis Business Conference
• The Transatlantic Triangle Under Pressure: Canada, Portugal, and Germany — Cannamonitor
• Is Portugal Losing Its Role as Europe’s Cannabis Gateway? — Business of Cannabis
• UK Medical Cannabis Data 2025: 262% Market Growth Analysis — Business of Cannabis
• Europe’s Cannabis Land Grab: The 30 Companies Leading EU Market Expansion In 2026 — International Cannabis Business Conference
• Cannabis — The Current Situation in Europe (European Drug Report 2025) — European Union Drugs Agency
• EU GMP Certification for Cannabis: Good Manufacturing Practice Guide — Cannabis Market Cap
• The Global Cannabis Trade in 2025: Price Compression, Regulatory Shifts, and Market Dynamics — StratCann
• Germany Cannabis Market Size 2026: EUR 670M Analysis — GrowerIQ
• Portugal’s Cannabis Exports Triple: 42 Tonnes to Germany — GrowerIQ
• Canada Cannabis Exports 240 Tonnes 2025 — GrowerIQ